期刊文献+

他克莫司纳米微球的制备及其体外释药性能

Preparation and release characteristics in vitro of tacrolimus nanospheres
下载PDF
导出
摘要 目的采用甲氧基聚乙二醇-聚乳酸聚合物(PEG-PLA)制备他克莫司微球(PPT),研究其体外释药特性。方法考察PPT的载药量、包封率、粒径大小、粒径分布和药物体外释放实验。结果PPT的制备工艺稳定、重复性好,微球外形圆整,表面光滑,分布均匀,平均粒径为(545.1±0.9)nm,平均载药量为(18.90±3.22)%,平均包封率为(25.0±1.6)%,35d的药物累积释放率为67.21%。结论他克莫司微球缓释时间长达35d,能够满足临床治疗的要求。 Objective To prepare tacrolimus nanospheres and study their physical state and release characteristics in vitro. Methods Tacrolimus nanospheres were prepared by emulsion-solvent evaporation method with PEG-PLA. The nanospheres were characterized in terms of morphology, size, encapsulation efficiency, the rate of drug loading and in vitro drug release. The physical state of PPT was determined by scanning electron microscopy (SEM) and dynamic light scatter ( DLS). Results The preparing technology was feasible. The formed nanospheres were spherical with smooth surfaces. The distribution of particle size was uniform and average particle size was (545.1 ±0.9)nm. The rate of drug loading was (18.90 ±3.22) % and the encapsulation efficiency was (25.0 ±1.6 ) %. In vitro release study revealed that the 35-day accumulated release percentage reached 67.21%. Conclusion The sustained release tacrolimus nanoshperes prepared by emulsion-solvent evaporation method can satisfy the clinical demand.
出处 《中国现代药物应用》 2008年第14期21-23,共3页 Chinese Journal of Modern Drug Application
基金 广东省科技攻关基金资助项目(2003C33812) 深圳市宝安区科技计划项目(2007035)
关键词 他克莫司 纳米微球 甲氧基聚乙二醇-聚乳酸聚合物 制备 体外释药 Tacrolimus FK506 Nanosphere PEG-PLA Emulsion-solvent evaporation method Preparation release in vitro
  • 相关文献

参考文献6

二级参考文献13

  • 1冯敏,潘仕荣,张静夏,王琴梅,吴伟荣,李瑞明.两性霉素B长循环纳米粒的研究[J].中国药学杂志,2005,40(15):1156-1159. 被引量:10
  • 2陈燕军,金日显,周雅琴,曾静,张鹤,冯青然.芎归散超临界CO_2萃取物固体脂质纳米粒的制备及体外释药特性评析[J].中国中药杂志,2006,31(5):376-379. 被引量:6
  • 3Sulaiman OA, Voda J, Gold BG,et al. FK506 increases peripheral nerve regeneration after chronic axotomy but not after chronic schwann cell denervation. Exp Neurol,2002,175:127-137.
  • 4Schmidt C, Wenz R, Nies B, et al. Application of the PLA implanted for treatment of the tumor. Pharm Res,1996,13:1059-1062.
  • 5Andersson J, Nagy S, Groth CG, et al. FK506 and cyclosporine inhibit antigen-or mitogen-induced monokine and lymphokine production in vitro. Transplant P roc,1992,24:321-325.
  • 6Thomson AW. Effect of combined administration of FK506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in humen mixed lymphocyte cultures. Tr anspl Immunol,1993,1
  • 7Steiner JP, Dawson TM, FotuhiC, et al. The immunosuppressant FK506 enhance p hosphorylation of GAP-43 :Implication for a role in modulation of growth cone function and neurotransmitter release. Soc Neurosci Abstr, 1991,18: 603- 608.
  • 8Beuche W, Friede RL. The role of non-resident cells in Wallerian degeneration. J Neurocytol,1984,13:767-770.
  • 9Fansa H, Keilhoff G, Horn T, et al.Stimulation of Schwann cell proliferation and axonal regeneration by FK 506. Restor Neurol Neurosci,2000,16:77-86.
  • 10W. Beuche,R. L. Friede. The role of non-resident cells in Wallerian degeneration[J] 1984,Journal of Neurocytology(5):767~796

共引文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部